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Abstract

CrkL, a 36 kD adaptor protein, is part of the Crk family of proteins which have
been implicated in a variety of human malignancies. CrkL is of special interest in
hematopoietic malignancies because of an increased level of expression in myeloid and
lymphoid derived cells lines. CrkL remains understudied but it has been shown to
interact with Bcr-AbI in chronic myelogenous leukemia (CML) and is currently being
used as a prognostic marker for patients by evaluating phosphorylation levels. Though
regulation of CrkL by tyrosine phosphorylation has been studied extensively, the role of
serine and threonine phosphorylation in an IL-2 dependent has not been characterized.
CrkL has been shown to respond to IL-2 stimulation in T lymphocytes but it’s role
in the Jak/STAT signaling pathway has not been well defined. This research used
radiolabeling and phosphoamino acid analysis to show increased levels of serine
phosphorylation upon IL-2 stimulation. Mass spectrometry analysis was then performed
to identify novel phosphorylated serine sites upon IL-2 stimulation and Calyculin A
treatment. Sites were aligned to determine conservation among species and were
chosen for site directed mutagenesis. Mutated CrkL will be characterized further in
future studies.
CrkL was shown to co-immunoprecipiate with protein phosphatase 1,PP1,
through mass spectrometry analysis and was further shown by completing CrkL
immunoprecipitations and PP1 immunoblots. The relationship between PP1 and CrkL is
important because PP1 may serve as a regulator of CrkL through serine de
phosphorylation.
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Chapter 1: Background and Significance
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1.1.Introduction

C10 oncogene homolog-like protein, CrkL, has been shown to have increased
expression in cancer cells with a resulting increase in cellular tyrosine phosphorylation
levels.[1] The Crk family plays a key role in recruiting [1] multi-protein complexes within
various signal transduction pathways. Multiple studies have suggested that Crk and CrkL
may be involved in human cancers. Immunohistochemical studies have shown Crk
overexpression in adenocarcinomas of the lung, breast, and stomach. Overexpression
has also been reported in sarcomas [1]. In a study of lung carcinomas increased CrkL
expression was used as a predictive factor of patient prognosis and survival.[2]
To determine the role of Crk several knockdown studies have shown Crk proteins
play a role in the phenotypic behavior of human tumor cells and are involved in regulating
transcription and cytoskeletal reorganization during cellular processes including growth
differentiation and death [1]. Knockdown of CrkL by siRNA in lung cancer showed a
decrease of tumor invasiveness, cell cycle progression, survival, and motility [2].
Crk proteins and CrkL in particular, have been understudied in hematopoietic
malignancies [2]. CrkL is especially relevant in hematopoietic cancers because it is more
highly expressed in myeloid- and lymphoid-derived cells [2]. CrkL known to be
phosphorylated by Abl tyrosine kinase, and to interact with Bcr-AbI in granulocytes and
myeloid precursor cells independent of phosphorylation [2]. CrkL phosphorylation by Abl
results in auto inhibition. In Bcr-AbI positive chronic myelogenous leukemia (CML) BcrAbl associates with CrkL independently of phosphorylation.[3]

2

1.2 Cancer
Cancer is a disease that results from the transformation of normal cells to a
neoplastic state.[4] It has evolved into the world’s leading cause of death[5], with
numbers that have doubled over the past three decades[6]. The rise in cancer related
deaths has been attributed to environmental and lifestyle related choices including
smoking, diet, and pollution, as well as a much longer life expectancy due to improved
medical care.[6] Cancer is expected to overcome heart disease as the leading cause of
death in the United States within the next few years.[7]
Cells gaining capabilities that allow them to become tumorigenic, and eventually
malignant, characterize the transition of cells from normal to neoplastic.[4] These six
traits have been identified as the hallmarks of cancer. The first trait is the ability to
sustain constant proliferation. Cancer cells inhibit the balance between growth and
death by deregulating signaling that normal cells employ. Transformed cells can employ
autocrine proliferative signaling by producing growth factors themselves. They may also
signal to normal cells around them to produce the growth factors they need to continue
growth.[8] It is also possible for cancer cells to up-regulate receptor expression so that
the cells can be hyper-sensitive to ligand, or for the cells to become independent of
signaling altogether.[4]
Cancer cells have also shown to result from somatic mutations that result in
constitutive signaling of downstream signaling that drives the disease. This has been
shown to be the case in human melanomas where approximately 40% of cases have
shown mutations in b-Raf that results in constitutive MAP signaling.[9] This has also
been shown in various tumors that demonstrate PI3K mutations.[10]
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Cancer cells have also shown an ability to disrupt negative feedback loops that
keep the growth balance in check.[4] The most important illustration of this ability is the
oncogenic mutation of Ras. Mutant Ras loses its GTPase abilities, which are necessary
for maintaining the negative feedback loop that hinders uncontrolled growth. This has
also been shown in the cases of PI3K signaling where PTEN phosphatase is not able to
counteract PI3K activity due to mutations.[11] This type of deregulation of negative
feedback loops can contribute to the development of resistance against therapeutic
agents that target mitogenic signaling.[4]
Another crucial aspect to the development of cancer is the cell’s ability to evade
growth suppressors commonly known as tumor suppressor proteins.[4] The two
prototypical tumor suppressor genes are Rb and TP53. Rb dictates whether the cell
shall proceed through the cell cycle based on factors outside of the cell. When Rb
experiences a mutation and results in a loss of function proliferation can continue
unchecked.[12] TP53 on the other hand operates based on information from within the
cell.[4] TP53 listens to signaling within the cell that signals for stress or abnormalities.
This can stem from excessive genome abnormalities, low levels of glucose, and levels
of available nucleotides. If conditions persist TP53 can trigger apoptosis.
Cancer cells also lose their ability for contact inhibition. In the case of normal
cells, they will cease growth if there is significant cell-to-cell contact.[4] Neoplastic cells
also gain an ability to resist cell death. Programmed cell death, apoptosis, is a vital part
of maintaining a healthy level of cells.[13] Apoptosis is mediated by two arms of
signaling within the cell, the regulatory branch and the effector branch. One branch
takes in and processes signaling from outside the cell while the other processes
signaling within the cell.[13] Ultimately both branches trigger proteases, caspase 8 or 9,
4

to initiate a cascade of caspases that handle proteolysis. The cell is taken apart by
these proteases and eventually consumed by its neighboring cells or phagocytic
cells.[4] On the other hand cell death by necrosis can actually be helpful to cancerous
cells.[14] While abnormal cells may orchestrate evasion of apoptosis they may actually
trigger necrosis of neighboring cells. The reason for this is that death by necrosis
recruits inflammatory cells of the immune system.[14] Inflammatory cells have the
capability to release factors that can stimulate neighboring cells to proliferate. [14]
Though cell death may seem like a good opposition to unregulated cell growth, in the
case of necrosis it can actually be detrimental.
Normal cells are only able to pass through a limited number of cell growth and
division cycles. In contrast, neoplastic cells can progress through the cycle and
unlimited number of times.[4] After a certain number of growth and division cycles cells
will either enter senescence or crisis. During senescence cells remain viable and stable
but no longer proliferate, while crisis leads to cell death. Cells that can avoid either of
these phases and continue growing are termed immortalized.[4] Immortalized cells have
shown increased telomerase activity.[15] Telomerase is an enzyme responsible for
adding repeats to the end of chromosomes to prevent degradation. Eventual
degradation of telomeres allow for the ends to join and to signal distress within the cell
that will result in apoptosis.[15] In the case of cancerous cells telomeres degradation is
greatly reduced and cells can maintain alive.
Tumors need the same requirements as normal cells, and to provide them they
need a developed vasculature developed through angiogenesis. During embryonic
development angiogenesis is heavily active, but soon after vasculature development
these cells become quiescent.[4] With the exception of wound healing and female
5

reproductive cycling, angiogenesis is generally turned off. When cancerous cells begin
to develop into a tumor angiogenesis is turned back on, and new vessels continually
develop to supply the tumor.[16] Angiogenesis is primarily controlled by factors that act
as either positive or negative regulators. Two well-known regulators of angiogenesis are
vascular endothelial growth factor A, VEGF-A, and thrombospondin-1, TSP-1. VEGF-A
can be upregulated by hypoxia or oncogene signaling[17] as well as held in the
extracellular matrix and eventually activated by extracellular matrix-degrading enzymes.
TSP-1 on the other hand is a counter balance that bind transmembrane receptors that
allow for suppressive signaling.[18]
Overall cancer is the disease that occurs when normal cells acquire various
abilities that allow them to continue uncontrolled proliferation, survival, and eventual
invasion and metastasis. Though many mechanisms that allow for this cellular
transformation have been elucidated there are a great many more that remain to be
defined.
1.3 Lvmghocvte Development and Activation
Lymphocyte precursors originate in the bone marrow, while development occurs
either in the thymus for T cells, or the bone marrow for B cells. T-cell mediated immunity
is an important component of the adaptive immune system and involves developing Tlymphocytes to specifically target viral, bacterial, parasitic infections or malignant
cells.[19] Maturation in the thymus results in each T-lymphocyte expressing a unique
receptor on the surface. Antigen specificity is determined early in differentiation when
coding sequences doe the receptor are assembled from gene segments. [20] The
receptor is then tested for recognition with ligand molecules that in its environment. If
the cell interacts weakly with self antigens then it will be selected to survive in a process
6

known as positive selection.[20] This is important for because T cells must recognize
MHC molecules when they are presented antigens in order to initiate an immune
response.[20] On the other hand cells that demonstrate high affinity for self molecules
will be signaled to die in a process termed negative selection.[20] This process is also
necessary because these cells could mount a dangerous autoimmune response. Most
cells die during development because their default course of action is death unless a
signal is received to continue and continue maturation in the peripheral lymphoid
organs.[20] The cells are then available for an adaptive immune response during which
clonal selection is employed.[20] Lymphocytes will continually circle through the blood
lymph and peripheral lymphoid organs looking for its specific antigen, and will continue
to do so until it is found or the lymphocyte is ready to die.[20]
T lymphocytes continue to circulate until they encounter the antigen that
corresponds to their receptor. Dendritic cells are known as antigen presenting cells,
APCs, and are capable of inducing a primary immune response by activating resting
nai”ve T lymphocytes. Follicular dendritic cells are also capable of maintaining immune
memory by interacting with B cells.[21] Dendritic cells are present in tissues that are
exposed to the environment such as skin, lungs, stomach, and intestines.[21] Once the
DCs have taken up the antigen it is processed by either an endosomal or proteosomal
pathway. [21] Dendritic cells process and present antigen for both CD4+ T helper cells
and CD8+ T cytotoxic cells; MHC class I cells present to stimulate CD8+ T cells, while
MHC class II cells present to stimulate CD4+ T cells.[21] Dendritic cells also possess
co-stimulatory molecules on their cell surface that are necessary for T cell activation.
Once activated T cells undergo clonal expansion and differentiation into effector or
memory T cells. The T cell receptor recognizes the antigen peptide on the MHC molecule,
7

and CD4 or CD8 co-receptors recognize the MHC molecule. Co-stimulation of APCs also
is required for full activation of T cells [22]. Co-stimulatory receptor CD28 binds to its
ligand CD80 on antigen presenting cells [22]. CD80 co-stimulatory events, along with
several other co-stimulatory events, lead to the production of a variety of cytokines that
can interact with cell receptors in either a paracrine or autocrine manner [23]. Interaction
with antigen on MHC molecule, co-stimulatory events, and autocrine and paracrine
signaling through cytokines are the three signals needed for full T cell activation. This
results in cell proliferation, differentiation, and survival [24]. Upon T cell activation,
expression of CTLA-4 receptors is induced as a way to temper T cell proliferation. CTLA4 receptors outcompete CD28 receptors for CD80 on APCs to prevent further T cell
expansion [25].
1.4 IL-2 Receptor and IL-2
The receptor for IL-2 is made up of three distinct subunits named alpha chain (IL2R-a), beta chain, (IL-2R-§), and gamma chain (IL-2R-y).[26] The receptor exhibits
highest affinity for its ligand, IL-2, when all three components are present but will function
without alpha chain. The most critical component is IL-R-§ and it has shown to be
physically and/or physically coupled with other signaling molecules.[26] IL-2R-§ has also
been shown to be involved in at least two intracellular signaling pathways that mediate
nuclear proto-oncogene induction.[26] The formation of the high affinity heterotrimer
receptor is not preformed but is instead driven by IL-2. IL-2 is captured by IL-2R-a through
a hydrophobic binding domain, which results in a relatively weak interaction.[27] This
interaction results in a conformational change of IL-2 that leads to association with IL-2R§. This complex will then recruit IL-2R-y and form the highest affinity form of the IL-2
receptor [27] and is found on activated T cells and mature dendritic cells.[28] The
8

intermediate affinity IL-2 receptor form includes beta chain and gamma chain and is
expressed on resting T cells, macrophages, immature dendritic cells and NK cells. [28]
IL-2R-a is an affinity conferring chain and is not involved in signal transduction
activity due to its short cytoplasmic chain; it is also not shared with any other interleukin
receptor, though it does exhibit structural similarity to IL-15R-a. [29] IL-2R-§ on the other
hand is shared with the IL-15 receptor and is involved with signal transduction. IL-2R-y is
also involved in signal transduction and is shared with the receptors for IL-2, IL-4, IL-7,
IL-9, IL-15, and IL-21, also known as the common gamma chain cytokines or the IL-2
family of cytokines.[30] Neither y or § subunits have catalytic activity, while both rely on
receptor-associated kinases to initiate cellular signal transduction. [30] The IL-2 receptor
complex can then by endocytosed by a clathrin-independent, dynamin-dependent
mechanism involving PI3K.[31]
IL-2R-a is made up of 272 amino acids and is 55kDa glycoprotein expressed on T
cells, NK cells and B cells.[32] IL-2R§ is 551 amino acids long with a molecular weight of
75 kDa and is expressed on neutrophils, T-, B-, NK-cells, dendritic cells and some
monocytes.[33] Beta chain has no catalytic activity and must be activated by receptorassociated kinases. It serves as a docking site for both Janus Kinase1 (JAK) and
JAK3.[33] Gamma chain is composed of 369 amino acids, is 64kDa, and is expressed on
NK, B, CD4+ and CD8+ T cells, neutrophils, granulocytes, monocytes, and
macrophages.[34] Like beta chain it has no intrinsic catalytic activity and has a region
used for JAK3 docking and activation.[28] Both gamma and beta chain are type I cytokine
receptors, contain fibronectin-III domains, and have three disulfide bonds.[28]
Interleukin 2 is a four bundle, a-helical protein of approximately 15 kDa produced
by antigen-activated T cells.[27] It can be produced by a variety of cells including NK,
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dendritic, mast, and CD8+ T cells, but is mostly produced by activated CD4+ T helper
cells.[27] In CD8+ cells IL-2 can stimulate growth and differentiation into memory
lymphocytes.[35] It is the main factor responsible for maintenance and differentiation of
CD4+ T regulatory cells.[35]
1.5 IL-2 Signaling
Once the receptor-ligand complex is assembled there are a set of signaling
pathways that may be initiated and these include the JAK/Stat, RAS/RAF/MEK/ERK, and
PI3K/Akt pathways.[36] These signaling pathways are mediated by a series of
phosphorylation and de-phosphorylation steps that can activate or shut off a protein.[36]
Phosphorylation can take place at tyrosine, serine, and/or threonine resides. Positive
regulation is mediated by the kinases that phosphorylate and negative regulation by the
phosphatases that de-phosphorylate.[36] Jak1 is associated with the IL-2R§ and Jak3 is
associated with y chain. Both Jaks will phosphorylate each other and when activated will
phosphorylate the receptor creating docking sites for STATs. [27] The STATs will dock to
phosphorylated tyrosine residues on the receptor and will then be phosphorylated
themselves.[24] The two STAT molecules will then hetero- or homo-dimerize and move
into the nucleus to affect gene expression. Tyrosine residues on the receptor also create
a docking site for Shc, an adaptor protein, that leads to the activation of the MAPK or
PI3K pathways.[27] The IL-2R complex is then internalized where IL-2R§, IL-2Ry, and IL2 are degraded and IL-2Ra is recycled to the surface to continue to recruit IL-2.[37]
Though three pathways diverge from the IL-2R, PI3K, MAPK, and STAT pathways,
they are not completely independent of each other.[37] It has been shown that a truncated
version of IL-2R§, that can only recruit Shc to the receptor, will have decreased activation
of downstream activators ofAkt.[38] Furthermore PI3K and STATE pathways do not show
10

full activation of their respective tyrosine residues are mutated. IL-2R subunits are
associated with the membrane at lipid rafts.[39]
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(B. Ruiz 2014)

Figure 1.1 IL-2 Signaling Pathways. Upon binding of IL-2 to IL2R-a Jak1 and Jak 3
are activated by autophosphorylation and then proceed to phosphorylate the receptor
creating docking sites for a variety of pathways. Phosphorylation of IL-2R§ creates a
docking site for Shc, which recruits Grb2 and Sos, which activates the
Ras/Raf/MEK/ERK pathway. This pathway activates transcription of genes involved in
cell survival and apoptosis. Shc also activates the PI3K/Akt pathway. Once PI3K is
activated it phosphorylates PIP2, which then becomes PIP3, which will then recruit PDK
to phosphorylate Akt. This pathway activates transcription of genes involved in
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1.6 PP1 and PP2A

1.7 CrkL
CT10 regulator of kinase (Crk) is the prototypical member of the Crk family of
proteins. This family is made up of Crkl, Crkll, Crklll, and CrkL[1]. They are a family of
adaptor proteins with no intrinsic enzymatic activity[3]. They are responsible for
recruiting proteins in a signaling cascade by forming multi-protein complexes. Crk, Crkll,
and Crklll are splice variants while CrkL is its own 38kD gene product. They are made
up of SH2 and SH3 domains separated by linker regions that facilitates protein
interactions [1]. SH2 domains are structurally conserved protein domains that bind
tyrosine phosphorylated proteins [3]. SH3 domains are also structurally conserved
protein domains that bind a consensus sequence of X1-P2-p3-x4-Ps where 1 and 4 are
aliphatic amino acids and 2 and 5 are always a proline [40].
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Figure 1.2: Crk Family Proteins
There are four members of the Crk family proteins and all are made up of SH2 and SH3
domains and function as adaptor proteins. Crk only contains one SH3 domain and no
characterized regulatory tyrosine residues. Crklll is the newest member to be identified
and contains a truncated SH3 domain. Crk II and CrkL are the most similar of the family
members as they share 56% homology and each have a regulatory tyrosine, Y221 and
Y207 respectively. Crk, Crk II, and Crk III are all splice variants while CrkL is not.
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CrkL and Crkll show the most similarity and are made up of SH2-SH3-SH3
domains [2]. A linker that includes a regulatory tyrosine residue separates the two SH3
domains. CrkL possesses an atypical C-terminal SH3 domain because it doesn't bind
polyproline type II containing motifs [2]. The C-terminal SH3 domain is thought to be
involved in allosteric regulation with Crk proteins or other proteins. It is seen in its
unphoshorylated state in fetal mouse tissue except for in the lung and brain in which
significant CrkIP is present [41]. It has also been show to associate with SOS and CG3,
indicating a role in signaling pathways of small GTPases of the ras family [41]. Along
with CrkL’s implications in cancer CRKL deletion mutants have shown cardiovascular
and craniofacial defects that led embryonic death [42].
Both Crk and CrkL are negatively regulated by auto inhibitory phosphorylation
that blocks its ability to function as an adaptor protein. Phosphorylation occurs at Tyr221
on Crk and Tyr 207 in CrkL and results in intramolecular binding of the linker region to
the SH2 domain. This binding prevents the SH2 and SH3N domains from binding other
proteins [1]. This type of auto inhibition is significant because it offers an explanation for
v-Crk’s transforming potential through deletion of the C-terminal regulatory element [2].
This type of negative auto regulation has similarly been shown in the Src family of
kinases through phosphorylation of the C-terminal domain [43]. The kinases
predominantly responsible for this phosphorylation are the proto-oncogene products Abl
and Arg tyrosine kinases [1]. Both the Crk and CrkL proteins are important for a broad
range of biological processes which include cell proliferation, cell adhesion and
migration, phagocytic and endocytic pathways for apoptotic cells, apoptosis, and
regulation of gene expression [1].
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The adaptor function of Crk is important for signal transduction in both
physiological and pathophysiological situations [1]. CrkL shares high homology with
Crkll structurally but development of knockout mice models show that they each have
distinct, non-overlapping functions during embryonic development [44]. They do not
have compensatory activity as it has been shown that knockout mice of each protein die
perinatally [44]. Additionally, other studies have shown that in Crk -/- models there is no
compensatory overexpression of CrkL, and vice versa [2]. These results indicate that
there is very little molecular crosstalk between the two.
Studies have shown that during development, Crkll and CrkL do not have
overlapping roles. However studies in somatic cells have the contrary. Various studies
have shown that Crkll and CrkL are co-expressed and can compensate each other in
cellular signaling as was showing in the Reelin signaling pathways of cortical pyramidal
cells of the hippocampus. Using shRNA and a cre-lox deletion system have provided
new insight into the universality of this compensation in signal transmission [1].
Crk/CrkL and Abl
Abl is a cellular homolog of v-AbI, an oncogene product of the Abelson murine
leukemia virus. It has been shown to be involved in cell growth, transformation,
apoptosis, cell stress, and remodeling of the actin cytoskeleton [45]. Abl phosphorylates
CrkL on tyrosine 207 and tyrosine 221 on Crkll, which results in the SH2 domain
associating with the phosphorylated tyrosine [3]. This auto inhibitory effect results in
inhibiting the binding of effector proteins and the subsequent signaling cascades.
Though the SH2 domain is blocked the SH3N domain is left available [3].
CrkL has shown to be more oncogenic than Crkll despite their structural similarities
[3]. CrkL has been shown to associate with Bcr-AbI in Chronic Myelogenous Leukemia
16

(CML) [46]. CrkL is constitutively associated with this aberrant protein independently of
phosphorylation of Y207,[3] but is shown to be constitutively phosphorylated in CML[47].
CrkL phosphorylation levels are even being used as a predictor of clinical outcome in
CML patients [48]. Bcr-AbI is a fusion protein that is the product of a reciprocal
translocation event resulting in the gene products of c-abl and bcr fusing. The generation
of Bcr-AbI is considered to be the initial event that leads to Philadelphia (Ph)chromosome positive leukemia [49]. The Bcr-AbI fusion protein demonstrates
degregulation of the Abl tyrosine kinase that leads to constitutive activity.
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Significance
Blood cancers are diseases that can affect the bone marrow, blood cells, lymph
nodes, and other parts of the lymphatic system.[50] It is estimated that approximately one
person every three minutes are diagnosed with a blood cancer in the United States.[50]
These new cases will account for 9.3% of the cancer diagnoses that will be reported 2015.
Leukemia is one form of cancer that affects white blood cells. Leukemia will account for
approximately 33% of the nearly 140,000 new cases of blood cancer this year that will
result in approximately 23,000 deaths.[50]
Leukemia causes more deaths than any other cancer among children and young
adults under the age of 20 and Hispanic children and adolescents under this age have
the highest incidence rates of this cancer.[50] This final statistic brings is of particular
importance to the region because of the high number of Hispanic individuals along the
border region.
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CHAPTER 2: IL-2 Induces CrkL Serine Phosphorylation
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2.1 Introduction
Investigating and determining the relationship between IL-2 stimulation and
serine phosphorylation is important because it can elucidate important regulatory
controls employed by CrkL within T cells. Because IL-2 is important for T cell
differentiation and growth it is of interest in determining whether it is capable of
stimulating CrkL serine and/or threonine phosphorylation. It has been previously shown
that post-translational modification is important for CrkL’s role in signal transduction
pathways. The most studied post-translational modification has been tyrosine
phosphorylation, especially at Y207, which can be stimulated by IL-2 [51]. To
investigate how serine and threonine phosphorylation play a role in CrkL activity and
whether IL-2 can stimulate that serine and/or threonine phosphorylation the following
experiments were performed.
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2.2 Materials and Methods
2.2.1 Cell Culture and Treatment
Human leukemic T cell lines Kit225 and YT were grown in RPMI 1640 (Thermo
Scientific Inc.) medium with 10% fetal bovine serum (FBS) (Atlanta Biologicals), 2 mM
L-glutamine (Cellgro), and penicillin-streptomycin (50 IU/ml and 50 pg/ml, respectively)
(Cellgro) (complete media) at 37 °C with 5% CO2. YT and Kit225 cells were made
quiescent by growing to exhaustion (» 5X10’ cells/mL and »8X10 ) and then stimulated
with 10,000 IU of human recombinant IL2 (NCI Preclinical Repository) for 10 minutes,
and/or treated with 100 nM CA (Sigma- Aldrich) for 15 minutes. Treatments were
performed at 37 °C using 20x106 cells per treatment.
2.2.2

lmmunoorecloitation. Westam Blot Analvsla, and Masa 9oectometrv
Cells were pelleted and solubilized in lysis buffer (10 mM Tris-HCI (pH 7.6), 5

mM EDTA (pH 8.0), 50 mM NaCI, 30 mM Na4P2O7. 50 mM NaF, 1 mM Na3VO4 , 1%
Triton X-100) containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 pg/ml aprotinin,
2 pg/ml leupeptin, and 1 pg/ml pepstatin A, and rotating at 4 °C for 1 h. Whole cell
lysates were clarified by centrifugation (15,000x g, 15 min, 4 °C). For
immunoprecipitation reactions, supernatants were rotated with 3 pg of a-CrkL rabbit
polyclonal antibody C-20 (Santa Cruz Biotechnology) for 2 hours at 4 °C. Immunocomplexes were captured by incubation with Protein A-Sepharose beads (Rockland
Immunochemicals) rotating for 1 h at 4 °C. The beads where then washed three times
with ice cold lysis buffer and eluted by boiling 5 min in 4 x SDS sample buffer (50 mM
Tris-HCI (pH 6.8), 100 mM dithiothreitol, 2% SDS, 0.02% promophenol blue, 10%
glycerol, pH 6.8). Samples were resolved in 10% SDS-PAGE and visualized by
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Coomassie blue staining.
SDS-PAGE (10% Acrylamaide) analysis was used to separate protein samples
once immunoprecipitated. Protein was then transferred to polyvinyl-difluoride (PVDF)
membrane and blocked with 1% bovine serum albumin (BSA) for 1 hour at room
temperature. Western blot analysis was the performed by incubating the membrane with
a-CrkL monoclonal antibody A-1 (Santa Cruz Biotechnology) or a-PP1 monoclonal
antibody E-9 (Santa Cruz Biotechnology). Assays were developed with horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse IgG (heavy plus light chains; KPL)
and visualized by using enhanced chemiluminescence and x-ray film. Bands
corresponding to CrkL were excised from Coomassie blue stained gel and sent to the
Taplin Biological Mass Spectrometry Facility (Harvard University) analysis through liquid
chromatography-tandem mass spectrometry (LC-MS/MS). Any protein with three or
more unique peptide matches was considered confidently identified. Manual
examination of the spectra as well as the probability- based score Ascore where used to
determine phosphorylation site localization.

:.z.J =r c›rth snhoau hata Labolln i and Phoanhoan lno Acid Anal'rsia
Kit225 and YT cells were starved to quiesence and labeled with [32P] orthophosphate
(Perkin-Elmer) for 2 hours at 37 °C. Cells were stimulated with 100 nM IL-2 for 15 minutes
and/or Calyculin A for 20 minutes. They were then pelleted and solubilized in lysis buffer
and rotating at 4 °C for 1 hour. Whole cell lysates were then clarified by centrifugation
(15,000x g, 15 minutes, 4°C). CrkL was immunoprecipitated with a rabbit polyclonal aCrkLantibody C-20 as described above. All proteins were separated by 10% SDS-PAGE
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and transferred to PVDF membrane and visualized by Coomassie Blue staining and
autoradiography. The corresponding protein bands were excised and subjected to two
dimensional phosphoamino acid analysis using the Hunter Thin layer electrophoresis
apparatus[52]. Bands were excised from the membrane and hydrolyzed with 7 M HCI for
30 minutes. Samples were then dried using a SpeedVac Concentrator for 1 hour. Sample
pellets were re-suspended and spotted onto TLC cellulose plates along with amino acid
standards. Plates were run in one direction at 1.5 kV for 25 minutes. Plates were then
rotated counterclockwise and run at 1.3 kV for 16 minutes. Plates were dried and sprayed
with Ninhydrin and baked for 15 minutes at 65°C. Film was exposed to plates for 3 weeks
and then developed. Labeling and phosphoamino acid analysis was repeated 6 times
with the same result.
2.2.4 Mutant Development
Once a novel serine phosphosite was identified a mutant was necessary to
characterize the residue. Serine 162 is in a unique location as it is right in the SH3N
domain, which is important for protein docking. Serine 162 also has an interesting
flanking region of EEQWWSAR, which includes two aromatic amino acids (W), two
charged residues (R, E), and one polar amino acid (Q). In order to determine the role of
serine 162 a serine to alanine mutant was generated by using the QuickChange site
directed mutagenesis kit (Agilent) according to manufacturer’s instructions. The primers
used for the mutation as follows: S126A (5’-CATCCTTGTTCCGGGCAGCCCACCACTG3’). The pcDNA human CrkL in a Pcmv6-Entry vector was purchased from Origene.
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2.3 Results
2.3.1 IL-2 and Calyculin A Treatment of CrkL and Western Blot Analysis
Samples (3X10^5) of Kit225 cells were either stimulated with IL-2, IL-4, IL-7, and
IL-9 for 15 minutes, Calyculin A for 20 minutes, or both. A control unstimualated sample
was also included. CrkL was immunoprecipitated and samples were separated by 10%
SDS-PAGE and transferred to PVDF membrane. Visualization of phosphorylated CrkL
was difficult to analyze by anti-phosphoserine and anti-phospho tyrosine antibodies so
molecular weight shifts were analyzed with a monoclonal a-CrkL antibody C-20. (Fig.1)
Samples showed an increased molecular weight when treated with CA, a known
PP1/PP2A inhibitor, as well as an appearance of an increased molecular weight band
with the treatment of the IL-2 family cytokines. The samples treated with CA or the
cytokine alone showed a double band while the combination of CA and the cytokine
showed a triple band indicating that the presence of both allows us to deduce that CrkL
is serine or threonine phosphorylated.
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Figure 2.1: IL-2 Cytokine Family Stimulates Appearance of Higher MW CrkL Band
Kit225 cells were left untreated (-), stimulated with IL-2, IL-4, IL-7, and IL-9 for 15 min
and/or treated with CA (100 nM) for 20 min. Cell lysates were immunoprecipitated (IP)
with a-CrkL and separated by SDS-PAGE. Samples were transferred to PVDF membrane
and immunoblotted with monoclonal a-CrkL antibody. Compared to the unstimulated (A)
sample there is an increased molecular weight band that appears in the CA stimulated
sample (B). Lanes with cytokine stimulation (C,G,E,I) also showed a second band of
increased molecular weight, and lanes with cytokine and CA show a third band of
increases molecular weight.
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Figure 2.2: IL-2 and Calyculin A Stimulate Higher Phosphorylation Levels of CrkL
Kit225 cells were starved to quiescence and were treated with [32P] orthophosphate for 2
hrs. at 37°C. Samples were left untreated (-), stimulated with IL2 for 15 min and/or
treated with CA (100 nM) for 20 min. Cell lysates were immunoprecipitated (IP) with aCrkL and separated by SDS-PAGE. Samples were transferred to PVDF membrane and
stained with Coomasie Blue to ensure equal protein levels. Protein bands were then
excised and subjected to phosphoamino acid analysis. Compared to the unstimulated
sample there is an increase of phosphorylated CrkL in the sample treated with CA (d) and
the sample treated with IL-2 for 15 min. (c) Sample treated with both showed the greatest
amount of phosphorylation.

27

B

TL-2

D

O"

”
Calyculin A + IL-2

Calyculin A

Ninhydrin

Autoradiograph

Ninhydrin

Autoradiograph

Figure 2.3: IL-2 and Calyculin A Stimulate Increased Serine Phosphorylation of
CrkL
Kit225 cells were starved to quiescence and were treated with [32Pj orthophosphate for 2
hrs. at 37°. Samples were left untreated (A), stimulated with lL2 for 15 min (B) and/or
treated with CA (100 nM) for 20 min (C)(D). Bands were excised from PVDF membranes
hydrolyzed with HCI for 30 min and transferred onto TLC cellulose plate. Phosphoamino
acid analysis was assessed for CrkL phosphorylation status.
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2.3.2 Identification of Novel Phosghoserine Sites in CrkL
In preparation for LC-MS/MS analysis YT cells (2X10^7) cells either left
unstimulated or treated with IL-2 for 10 minutes, IL-2 for 15 minutes, CA for 20 minutes,
or a combination of CA for 20 minutes followed by IL-2 for 15 minutes. Cells were lysed
and immunuprecipitation was performed with a-CrkL rabbit polyclonal and protein was
separated by 10% SDS-PAGE and visualized by Coomassie Blue staining. (Figure
2.4a) To ensure cells were quiescent a small aliquot of the sample was analyzed for
STAT5b activation with a phospho-specific a-STAT5b (Figure 2.4). Bands
corresponding to CrkL (37kD) were excised, subjected to trypsin and Asp-N digestion,
and analyzed by liquid chromatography-tandem mass spectrometry. YT Spectra
analysis using the Sequest search algorithm revealed a combined protein coverage of
73% for the non-treated sample, 76% for IL2 stimulated, 76% for CA treated cells, and
68% for IL-2 + CA, as well as the identification of several novel CrkL phosphorylated
peptides. (Figure 2.5) Phosphopeptides were identified which included phosphorylated
S184, which appears to be constitutively phosphorylated and has been previously
identified. Y127, Y207, the regulatory tyrosine located in the linker region between the
SH3 domains, appear phosphorylated in the IL-2 sample. S185 appears phosphorylated
in the Fsk sample which has not been previously identified. S162 appears in the IL-2
and CA stimulated samples but not in the unstimulated or Fsk sample indicating it is IL2 and CA inducible. S162 is a novel phosphoserine site.
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2.3.3 PPI Interacts With CrkL
LC-MS/MS results showed that CrkL co-immunoprecipitated with protein
phosphatase 1 (Table 2.2). Considering the increased level of CrkL serine
phosphorylation when treated with Calyculin A and the physical interaction
demonstrated through mass spectrometry there could be a relationship between PP1
and CrkL. Kit225 cells (3X10^6) were left either unstimulated or treated with IL-2 for 15
minutes, CA for 20 minutes, or both IL-2 for 15 minutes and CA for 20 minutes.
Samples were lysed and CrkL was immunoprecipitated with a-CrkL antibody and
protein was separated by 10% SDS-PAGE. Western blot analysis with a mouse
monoclonal a-PP1 antibody showed an increased amount of PP1 with IL-2 stimulation,
and no detectable PP1 with Calyculin A present indicating a role for PP1 in CrkL
negative regulation. (Figure 2.7)
Calyculin A is a PP1/PP2A inhibitor and due to that we also wanted to look at any
interaction between PP2A and CrkL. Mass spectrometry samples did not show any coimmunoprecipitation with PP2A in any of the treatments. Kit225 cells (3X10^6) were left
either unstimulated or treated with IL-2 for 15 minutes, CA for 20 minutes, or both IL-2
for 15 minutes and CA for 20 minutes. Samples were lysed and CrkL was
immunoprecipitated with a-CrkL antibody and protein was separated by 10% SDSPAGE. Western blot analysis with a mouse monoclonal a-PP2a antibody showed no
detectable presence of PP2A with any of the treatments. (Figure 2.8) Furthermore
samples were probed with PP2A antibodies (Cell Signaling) against either subunit A, B,
C with no detectable presence of PP2A.

29

A.
kDa

a

b

c

100 kDa
P-STAT5B

Treatment:
Time:

IL-2
IL-2
10 min. 15 min.

Total Cell LYsate
WB: pSTAT5

B.
kDa
a

b

d

e

37

CrkL

Treatment:
Time:
IP: CrkL
Stain: Coomassie

30

Figure 2.4: Immunoprecipitation of CrkL for Mass Spectrometry
YT cells were starved to quiescence and were left untreated (-), stimulated with lL2 for
15 min and/or treated with CA (100 nM) for 20 min. Sample was separated by 10%
SDS-PAGE and sent for LC-MS/MS analysis.
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Table 2.1: LC-MS.MS Identification of Phosphorylation Sites in CrkL

Coverage

IL-2 1O min.

7006

Phoepho Residues

S184,S&6],Y127

.58
Calyculin A

74.59•#

S162

Table 2.1: LC-MS.MS Identification of Phosphorylation Sites in CrkL
YT cells were starved to quiescence and were left untreated, stimulated with IL2 for 15
min and/or treated with CA (100 nM) for 20 min, or treated with Forskolin for 20 min.
Phosphopeptides were identified which included phosphorylated S184, which appears
to be constitutively phosphorylated and has been previously identified. Y127, Y207, the
regulatory tyrosine located in the linker region between the SH3 domains, appear
phosphorylated in the IL-2 sample. S185 appears phosphorylated in the Fsk sample
which has not been previously identified. S162 appears in the IL-2 and CA stimulated
samples but not in the unstimulated or Fsk sample indicating it is IL-2 and CA inducible.
S162 is a novel phosphoserine site.
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Phosphopeptide: KGEILVIIEKPEEQWWSAR
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Figure 2.5: Identification of Novel Phosphorylation Sites on Human CrkL
LC-MS/MS analysis showed an IL-2 and Calyculin A inducible site on CrkL at serine 162
indicated in red. Previously identified phosphorylated amino acid residues are shown in
black. Serine 162 is located within the SH3N domain.
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Figure 2.6: Tandem Mass Spectra and Sequence Conservation of CrkL S162
(A)Tandem mass spectra of a monophosphorylated peptide showing site localization of
S162 on IL2 and CA stimulated YT cells, as indicated by asterisks. (B) Amino acid
sequence alignment of the region surrounding S162 from different organisms using
CLUSTAL OMEGA program. Conservation of S162 across species as well as the
surrounding sequence containing aromatic tryptophan (W) make it an interesting site for
involvement in regulation.

34

Table 2.2 LC-MS/MS Analysis CrkL Co-Immunuprecipitation

t
Total
reference
Unique
30
362 P461O9_CRKL HUMAN

2.8424 CRKL

33.76

16

17

P35579_MYH9_HUMAN

3.5251 MYH9

226.39

16

16

PO7355_,ANXA2 HUMAN

3.2350 ANXA2

38.58

14

38

P539O7_CAZA 1 HUMAN

3.1374 CAPZA1

32.90

12

22

P22626_ROA 2 HUMAN

2.6179 HNRNPA2B 1

37.41

12

12

PO4O4O CATA HUMAN

3.2753 CAT

59.72

11

12

PO278B_TRFL HUMAN

3.0706 LTF

78.13

11

11

QO2B78_RL6_HUMAN

2.5480 RPL6

32.71

10

11

QO9666 AHNK_HUMAN

2.5268 AHNAK

628.70

9

9

P42357_HUTH_HUPgAN

2.8925 HAL

72.65

8
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PO44OS_G3P HUMAN

2.8968 GAPDH

36.03

8

14

P461O8_CRK_HUMAN

2.9049 CRK

33.81

8

10

Q5M7ZO_RNFT 1_HUMAN

2.7967 RNFT1

49.68

7

17

IGHG RABIT

2.3776

35.38

PO4OB3 ANAA1_.HUMAN

3.6017 ANXA1

38.69

7

AVG

Gene Symbol

gWT{kDa)

Table 2.2: LC-MS/MS Analysis CrkL Co-Immunuprecipitation
Kit225 cells were left untreated (-), stimulated with IL-2 for 15 min and/or treated with CA
(100 nM) for 20 min. Cell lysates were immunoprecipitated (IP) with a-CrkL and separated
by SDS-PAGE. Samples were transferred to PVDF membrane and immunoblotted with
monoclonal a-PP1 antibody. IL-2 stimulated lane (B) shows an much larger amount of
PP1 associated with it when compared to the unstimulated lane (A). Samples with CA
treatment show an absence of PP1 signal indicated that the inhibitor disrupted the
interaction between CrkL and PP1.
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Figure 2.7: IL-2 Stimulated Kit225 Cells Co-lmmunoprecipitate with PP1
Kit225 cells were left untreated (-), stimulated with IL-2 for 15 min and/or treated with CA
(100 nM) for 20 min. Cell lysates were immunoprecipitated (IP) with a-CrkL and separated
by SDS-PAGE. Samples were transferred to PVDF membrane and immunoblotted with
monoclonal a-PP1 antibody. IL-2 stimulated lane (B) shows an much larger amount of
PP1 associated with it when compared to the unstimulated lane (A). Samples with CA
treatment show an absence of PP1 signal indicated that the inhibitor disrupted the
interaction between CrkL and PP1.
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Figure 2.7: IL-2 Stimulated Kit225 Cells do not Co-lmmunoprecipitate with PP2A
Kit225 cells were left untreated (-), stimulated with IL-2 for 15 min and/or treated with CA
(100 nM) for 20 min. Cell lysates were immunoprecipitated (IP) with a-CrkL and separated
by 10% SDS-PAGE. Samples were transferred to PVDF membrane and immunoblotted
with monoclonal a-PP2A antibody. All lanes show no signal in the range of PP2A
molecular weight.
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Chapter 3: Overview and Future Directions
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3.1 Overview
IL-2 is essential for activation of T, B, and NK cells as well as being the main
driver for T cell proliferation. IL-2 signaling has been shown to be mediated by the IL2R
which is tyrosine and threonine phosphorylated to create a docking site for STATs and
adaptor molecules such as Shc, which will continue down the PI3K and/or the MAPK
pathways. Adaptor molecules, such as CrkL, involved in these pathways are necessary
for assembling protein networks and mediating protein interactions. These major
pathways leading to T cell proliferation serve as targets for therapeutic agents against
malignancies.
The Crk family proteins are adaptor proteins implicated in various types of
malignancies including glioblastoma and gastric, prostate, ovarian, breast, and lung
cancers. CrkL is of unique importance in hematopoietic malignancies because of an
increased level of expression in myeloid and lymphoid derived cells lines. CrkL remains
understudied in hematopoietic cancers and could function as a possible therapeutic
target.
It has been previously reported that CrkL is tyrosine phosphorylated with IL-2
stimulation and work in our lab has shown increased levels of serine phosphorylation
with IL-2 stimulation (Fig 2.3). Considering the role of adaptor proteins in signaling
networks we sought to investigate whether IL-2 can stimulate serine phosphorylation of
CrkL and the regulation of CrkL by serine/threonine phosphatases PP1 and PP2A.
The first objective of this thesis was to determine whether IL-2 can induce serine
or threonine phosphorylation, and then to determine which residues if so. The first step
was stimulating quiescent Kit225 and YT cells with IL-2 and the IL-2 family of cytokines
(Figure 2.1) which share the common gamma chain, as well as including samples pre39

treated with Calyculin A, a known serine/threonine phosphatase inhibitor. Western blot
analysis showed the appearance of a double band correlating to a higher MW CrkL
when stimulated with IL-2 family cytokines, and a triple band when treated with
Calyculin A (Figure 2.1). This result indicated that IL-2 family cytokines stimulate the
appearance of a modified CrkL and that CA enhances the result, pointing to a
relationship between CA and the modification.
To investigate the effect of IL-2 and CA treatment on CrkL [32P] orthophosphate
labeling and phosphoamino acid analysis was performed on CrkL bands. Results
showed an increased amount of CrkL phosphorylation in IL-2 and IL-2 with CA
samples. Furthermore PAA showed an increased amount of serine phosphorylation
in IL-2 and IL-2 with CA samples. (Figure 2.3)
To map which serine residues were being phosphorylated we employed
immunoprecipitation of CrkL and identification of phosphopeptides through LC-MS/MS.
We identified S162 to become phosphorylated in response to IL-2 stimulation as
well with CA treatment. The novel IL-2 inducible S162 site was then examined via
sequence alignment software to determine whether the residue and the region
surrounding was conserved across different species. The phosphopeptide was
shown to be highly conserved across species. In order to characterize this site a
mutant S162A was generated using site directed mutagenesis.
LC-MS/MS analysis showed a variety of proteins that co-immunoprecipitated with
CrkL and one of them was protein phosphatase 1. Due to response to CA the
appearance of PP1 was further investigated by co-immunoprecipitations of CrkL with
PP1. Results showed that when Kit225 cells were stimulated by IL-2 there is an
increased amount of PP1 associated with CrkL while the introduction of CA
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reduces the amount of PP1 associated with CrkL. Calyculin A is a PP1/PP2A
inhibitor so PP2A was also analyzed by co-immunoprecipitation. Coimmunoprecipitation results show no PP2A associated with CrkL for any of the
treatments. Furthermore PP2A was not shown to co-immunoprecipitate with CrkL by
LC-MS/MS.

Kinase consensus predictive software (KinasePhos 2.0) determined the

phosphopeptide contains a sequence that could be phosphorylated by Akt 1 or
MAPK with MAPK having the higher SVM score. The software predicted serine
kinases that are involved IL-2 signaling. Using this as a starting point we could use
selective inhibitors of MAPK and Akt1, such to see if there is a decreased level of CrkL
phosphorylation.
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Figure 3.1: Model of CrkL in IL-2 Signaling Pathway
CrkL has been shown to form a complex with Grb2, SOS, and Shc. Our work has shown
that IL-2 stimulation results in increased serine phosphorylation. Kinase prediction
software determined that a MAPK consensus sequence exists within CrkL indicating a
possible role for either ERK 1 or ERK2 as a kinase for CrkL. PP1 has also been shown to
have a regulatory relationship involving CrkL phosphorylation.
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3.2 Future Directions
The previous data demonstrated that CrkL serine phosphorylation is inducible by
IL-2 but the role of the phosphorylation needs to be studied. Characterization of the
mutant by radiolabeling, PAA, and co-immunoprecipitations should be performed in the
future. Furthermore the kinase responsible, our target being ERK1/2, for
phosphorylating the IL-2 inducible serine will need to be determined to further
understand where along the cascade CrkL plays a role. To do this selective kinase
inhibitors should be used to target certain known serine/threonine kinases and
determine the effect on CrkL serine phosphorylation. Data from these experiments can
be taken further by knockdown experiments of the kinase by siRNA and looking at
levels of CrkL phosphorylation
To further investigate the relationship between CrkL with and PP1 selective
phosphatase inhibitors can be used to determine the effect on CrkL.
Immunoprecipitation, Western blot analysis, and radiolabeling could be used to visualize
the effect. These experiments would need to be followed with knockdown of PP1 to
corroborate the relationship with CrkL by looking at the serine phosphorylation levels of
CrkL. If there are increased levels of phosphorylation when PP1 is knocked down we
could confidently state that PP1 plays a negative regulatory role of CrkL serine
phosphorylation.
Lastly, and most importantly, would be to generate a phospho-specific antibody
against CrkL serine 162. An antibody would allow one to readily characterize the role
that serine phosphorylation of CrkL can play in cellular signaling networks. A specific
antibody can be used for testing in primary malignant cell samples to determine if serine
162 phosphorylation levels differ from non-cancerous cell samples. Ultimately this work
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could be used to determine the role of CrkL S162 phosphorylation in disease and how it
can be targeted for therapeutic purposes in hematopoietic malignancies by exploring
options that could inhibit or enhance CrkL serine phosphorylation depending on the role
it is playing in signaling networks.
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